Novo Nordisk A/S (Novo Nordisk A/S) 3-Year Revenue Growth Rate : 24.00% (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Novo Nordisk A/S 3-Year Revenue Growth Rate?

Novo Nordisk A/S's Revenue per Share for the three months ended in Dec. 2023 was $2.15.

During the past 12 months, Novo Nordisk A/S's average Revenue per Share Growth Rate was 32.70% per year. During the past 3 years, the average Revenue per Share Growth Rate was 24.00% per year. During the past 5 years, the average Revenue per Share Growth Rate was 16.70% per year. During the past 10 years, the average Revenue per Share Growth Rate was 10.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Novo Nordisk A/S was 127.90% per year. The lowest was -46.20% per year. And the median was 10.40% per year.

Competitive Comparison of Novo Nordisk A/S's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Novo Nordisk A/S's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Novo Nordisk A/S's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Novo Nordisk A/S's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Novo Nordisk A/S's 3-Year Revenue Growth Rate falls into.

Novo Nordisk A/S 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Novo Nordisk A/S (OTCPK:NONOF) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Novo Nordisk A/S 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Novo Nordisk A/S's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Novo Nordisk A/S (Novo Nordisk A/S) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novo Nordisk A/S (OTCPK:NONOF) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

NVO:USA NOVOB:Mexico NVO:Mexico NOVOBc:UK 0QIU:UK NOVO B:Denmark NOV:Germany N1VO34:Brazil NNO2:Austria

Address

Novo Alle 1, Bagsvaerd, DNK, DK-2880

Website

https://www.novonordisk.com

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.